Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | CheckMate 214 trial in RCC updates

David McDermott • 15 Feb 2019
GU Cancers 2019
Genitourinary Cancer Kidney Cancer Checkpoint Inhibitors Ipilimumab Nivolumab Sunitinib
CheckMate 214

Prof. David McDermott, MD, of Beth Israel Deaconess Medical Center, Boston, MA, discusses results from the Phase III Checkmate 214 trial, which brought PD1 blockers into the frontline of renal cell carcinoma (RCC) treatment. Prof. McDermott explained that nivolumab administration in combination with ipilimumab improved previously untreated RCC overall survival, when compared with sunitinib. This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from David McDermott

1:30
RCC treatment: future remarks
David McDermott • 15 Feb 2019
2:31
Recent immunotherapy advances in RCC
David McDermott • 15 Feb 2019

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals